Tesamorelin turns on genes that help mitochondria burn fat more efficiently by improving oxidative phosphorylation and fatty acid oxidation, leading to cellular-level metabolic remodeling.

Tesamorelin upregulates nuclear-encoded genes involved in mitochondrial oxidative phosphorylation and fatty acid β-oxidation.

Tesamorelin and MOTS-c act synergistically: tesamorelin enhances fat mobilization, fat quality, and mitochondrial capacity for fat burning, while MOTS-c improves mitochondrial fuel utilization efficiency through AMPK activation, creating a complementary supply-and-utilization mechanism.

Visceral fat is metabolically active tissue that disrupts insulin sensitivity and metabolic function, and tesamorelin reduces it through mechanisms that improve fat quality, muscle composition, and mitochondrial efficiency, leading to long-term metabolic resilience.

Tesamorelin has robust human evidence demonstrating specific reductions in metabolically harmful fat depots including visceral, liver, and intramuscular fat.

Tesamorelin independently increases fat density in visceral and subcutaneous adipose tissue, indicating improved fat quality with smaller adipocytes, better vascularization, reduced hypoxia, and decreased inflammation, independent of fat quantity changes.